SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 139 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $355 | -26.2% | 24,410 | +6.4% | 0.00% | – |
| Q2 2023 | $481 | +99.6% | 22,939 | +101.9% | 0.00% | – |
| Q1 2023 | $241 | +1.3% | 11,364 | +21.4% | 0.00% | – |
| Q4 2022 | $238 | -99.9% | 9,364 | +11.1% | 0.00% | – |
| Q3 2022 | $203,000 | -97.9% | 8,429 | -98.4% | 0.00% | -100.0% |
| Q3 2021 | $9,863,000 | +36.6% | 516,098 | +22.8% | 0.00% | 0.0% |
| Q2 2021 | $7,219,000 | -26.5% | 420,420 | -4.2% | 0.00% | 0.0% |
| Q1 2021 | $9,816,000 | +157.4% | 439,017 | +156.1% | 0.00% | – |
| Q4 2020 | $3,813,000 | – | 171,439 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |